American Shared Hospital Services (AMS) Earnings Call Transcript & Summary

April 2, 2020

NYSE American US Health Care Health Care Providers and Services earnings 27 min

Earnings Call Speaker Segments

Stephanie Prince

executive
#1

Thanks, Daryl, and I appreciate all of you being on the call today. Before we hand things to management, I'd like to offer a few comments regarding forward-looking statements. Be aware that a number of things we might say during this conference call regarding future expectations, plans and prospects for the company count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements suggest, owing to a range of important factors, among them the ones covered in the company's SEC filings. Those filings include the annual report on Form 10-K and the quarterly reports on Form 10-Q covering each of the 3 quarters of 2019 that ended March, June and September, plus the definitive proxy statement for the Annual Meeting of Shareholders that took place on June 21, 2019. The company takes on no obligation to update any information in this conference call. At this point I'd like to hand the call to Craig Tagawa, Chief Operating and Financial Officer. Craig?

Craig Tagawa

executive
#2

Thanks, Stephanie, and good afternoon, everyone, for joining our Fourth Quarter and Year-end 2019 Earnings Conference Call today. To start, I'll take you through how our business and operations performed. Alexis Wallace, who serves as our controller, will follow with a review of the financials. After that, Dr. Bates, Alexis Wallace, Ernie Bates, and I will take your questions. Moving to the fourth quarter, our proton therapy business kept delivering solid growth, as revenue for the Orlando Health proton therapy system rose 4.7% to $1.486 million, lifted by greater volumes. Proton therapy fractions for the quarter totaled 1,611, an increase of 67, or 4.3% quarter-over-quarter, versus 1,544 in the fourth quarter of 2018. Across the full year, proton therapy revenue grew 23%, while fractions climbed 17%. Awareness of the clinical advantages and the widening applications of proton therapy treatment keeps rising, and that will underpin further growth of this vital cancer therapy. Gamma Knife revenue for the fourth quarter was up 4.1%, reaching $3.230 million. Gamma Knife procedures rose by 60 in the fourth quarter, hitting 414, compared with 354 in last year's fourth quarter. This procedure growth came from the ongoing ramp-up of our stand-alone facility in Lima, Peru, along with the addition of our new site in Merrillville, Indiana, which started treating patients in January 2019. On the whole, the Gamma Knife business saw higher volume but lower average reimbursement in the fourth quarter. During the first quarter of 2020, we finished 2 Cobalt-60 reloads and signed a contract for an Icon upgrade with existing customers. As previously disclosed, we've also kept up discussions with interested parties regarding additional PBRT and MR-Linac placements. That said, we realistically anticipate these conversations will slow as the country and the health care system keep grappling with the COVID-19 pandemic. We do anticipate COVID-19 will affect our business. For the proton therapy business, which mostly treats patients with cancerous tumors, we don't anticipate a significant impact. If patients keep getting diagnosed in a timely manner, we expect volumes to hold steady in the near term. That said, roughly 40% of Gamma Knife procedures are viewed as nonurgent and could face delayed treatment because of COVID-19, and we are seeing some softening in volumes at sites in March. We anticipate a greater impact in the second quarter, though it's difficult to be more specific right now. As our press release noted this morning, and as we discussed on our third quarter conference call in July 2019, the Centers for Medicare and Medicaid Services announced a proposed new mandatory payment model for radiation oncology services, meant to test an episodic payment structure, or bundled payment, across certain radiation therapy providers and suppliers. CMS estimates that about 40% of radiation oncology providers will be randomly selected and included in this model, while approximately 60% will keep receiving reimbursement under the current fee-for-service methodology. Under the proposed payment model, CMS would have made substantial changes to how it pays for radiation oncology services. For the 60% of centers that the proposed model does not cover, Medicare reimbursement in 2020 for the proton therapy delivery codes used most often is proposed to rise to roughly 15.5%, while for the Gamma Knife it is proposed to rise 3.6%. When the proposed payment model would take effect and what it would involve are still unclear. Because of that, we are unable to gauge what effect adopting the proposed rule might have. That said, our revenues and financial results could be harmed by lower reimbursement rates or by shifts in how reimbursement for radiosurgery and radiation therapy is determined or administered. We will pass along any new information we get, though in the current environment it is probably wise to anticipate a delay. With that, I will now hand the call over to Alexis for a detailed financial discussion. Alexis?

Alexis Wallace

executive
#3

Thanks, Craig. Hello, everyone, and good afternoon. Before I get into my prepared comments, I want to direct your attention to the earnings results for our fourth quarter and year-end 2019, which came out this morning. A copy of that earnings release is available on our website, ashs.com, under the Investors tab in press releases. For the 3 months ended December 31, 2019, revenue came in at $4.786 million, which was consistent with the $4.770 million we recorded in the fourth quarter of 2018. Revenue in the fourth quarter from our proton therapy system installed at Orlando Health in Florida rose 4.7% to $1.486 million, compared with $1.419 million in the fourth quarter of 2018. Revenue from the company's Gamma Knife operations rose 4.1% to $3.230 million in the fourth quarter of 2019, compared with $3.102 million in the fourth quarter of 2018. That increase reflected higher volumes at existing sites, offset by lower average reimbursement at the company's retail sites. Gross margin in the fourth quarter of 2019 fell to $1.441 million, or 30.1% of revenue, compared with gross margin of $1.565 million, or 32.8% of revenue, in the fourth quarter of 2018. The decline stemmed from higher depreciation on the Gamma Knife's IGRT equipment at a customer location whose contracts are set to expire in the second quarter of 2020. Net income in the fourth quarter of 2019 was $193,000, or $0.03 per share. That compares with net income of $178,000, or $0.03 per share, in the fourth quarter of 2018, and $165,000, or $0.03 per share, in the third quarter of 2019. Adjusted EBITDA, a non-GAAP financial measure, was $2.056 million in the fourth quarter of 2019, compared with $2.346 million in the fourth quarter of 2018. On the balance sheet at December 31, 2019, cash, cash equivalents and restricted cash totaled $1.779 million, compared with $1.792 million at December 31, 2018. Shareholders' equity at December 31, 2019, was $31.811 million, or $5.47 per outstanding share; that compares with shareholders' equity at December 31, 2018, of $31.048 million, or $5.43 per outstanding share. Issued outstanding shares totaled 5.817 million at December 31, 2019, compared with 5.714 million at December 31, 2018. That wraps up the formal portion of our presentation. Daryl, we'd like to hand the call back to you now for questions.

Leonard Dunn

analyst
#4

Yeah. Of course, I get that in the situation right now there's only so much you're able to say, and clearly everybody is holding onto the hope that the nation begins reopening a bit around the middle of May or the start of June, though nothing is assured on that front, and until this is under better control, hospitals won't be performing elective procedures; so my usual questions aren't there because I realize all of it is paused, but I'd actually be curious to hear your medical perspective on what you think about reopening and preparing for a possible second wave later in the fall; anyway, that's basically the single thing I'd ask.

Craig Tagawa

executive
#5

At this moment, I'd say it's clearly not known, and folks are laboring very hard to develop treatments or vaccines that can fight this, but my sense is it's still too soon to say. And all of us are hoping this concludes in a relatively brief stretch, yet there are plainly no assurances regarding how long it will go on.

Leonard Dunn

analyst
#6

Okay, that makes sense. From my own perspective, I fall into the group that basically has to stay isolated and can't even visit my grandchildren until things are more under control. So I'm eager for this to be over, like just about everyone across the country, I'd guess, but I have nothing further to add.

Analyst

analyst
#7

I've seen that the balance in your accounts receivable has been climbing. It's risen 170%. Yet — across the last 4 years, your provision for doubtful accounts has stayed flat at $100,000. Would you address that, please?

Craig Tagawa

executive
#8

Alexis, I'll have you take that one.

Alexis Wallace

executive
#9

Right. The main reason it's going up has to do with our proton therapy, since on a monthly basis that site carries significantly bigger accounts receivable, and then year-end can be affected by how many months' worth we'd managed to collect. So in January we brought in a fair amount tied to that unit, plus a couple of other sites that were carrying some sizable unpaid balances. So you'll see — you should see that come down during the first quarter. Broadly speaking, though, it runs higher because of the volume flowing out of our proton therapy site.

Tony Marchese

analyst
#10

There are two things I want to ask about. To begin with, I didn't quite follow you when — I suppose what's puzzling me is the point at which you brought up the CMS adjustments; all things considered, if there are no other modifications, do those CMS adjustments work in AMS's favor?

Craig Tagawa

executive
#11

When viewed through the lens of the Gamma Knife, our take is that the effect is neutral. As for the proton system, beneath the updated rules — though whether these are truly final remains uncertain — reimbursement for protons could go down in the sense that, at present, protons, as you're aware, get paid per fraction, whereas the new approach would rest on the cancerous indications being treated. From a Medicare perspective, then, this might mean a reduction in what's paid for a course of treatment.

Tony Marchese

analyst
#12

Alright. About proton beam — I'm aware that you folks have mentioned possibly bringing in additional proton beam therapy. My guess is that it's paused, but has that chance disappeared? Or is it simply paused? What word would you use for how those discussions stand right now?

Craig Tagawa

executive
#13

Anthony, I'm going to have Ernie Bates take that one.

Ernest Bates

executive
#14

Tony, it's Ernie Bates here. How's it going? Would you mind asking that question one more time? My apologies — I was stuck waiting outside.

Tony Marchese

analyst
#15

Put another way — no worries, that's fine. During the previous conference call, you folks mentioned having the ability to bring on a number of proton beam locations. With everything that's gone on regarding COVID, have those talks been paused right now? Or are they disappearing? Are they still moving forward? I'm simply wondering where you stand, or at least what you think, as of now?

Ernest Bates

executive
#16

Absolutely, Tony. Yeah, I'd say that largely speaking, conversations about protons or building additional proton centers are on hold at the moment, yet our possible clinical partners keep showing interest in bringing proton therapy into their facilities. There's a single location where talks remain active, and there's enthusiasm there for creating a radiation therapy center, which in the end would feature a one-room proton therapy system and facility; therefore, we're still in discussions with the prospective hospital and clinical partner regarding that.

Tony Marchese

analyst
#17

Right. Also, you had mentioned at some stage that a second machine could potentially be added at your Florida facility. Did anything come of that? Or does it remain a possibility?

Craig Tagawa

executive
#18

It remains a possibility, and by now it has been analyzed; however, similar to all other things, progress was slowed by what is going on in the health care environment.

Tony Marchese

analyst
#19

Right, okay, yes. My worry here is really only about the equity side of things. If I've got this right, you've reported tangible book value per share near $5, while the shares trade at $1.45, so I'm puzzled about what explains that gap. I don't really expect an answer from you on it — maybe it's simply an oddity. But one last item I wanted to raise concerns the Care Act plus several other programs the federal government is now making available to companies. Are you intending to — do you meet the criteria? Or are you intending to make use of it?

Craig Tagawa

executive
#20

Honestly, Anthony, we're going to need to examine that and determine whether we'd be eligible.

Tony Marchese

analyst
#21

All right. I realize I'm not the one running your business, of course, but it appears to me you'd be eligible, and a few of the items on offer strike me as something that would help your team a great deal. So I'm sure you don't need me saying this, yet my read is that you are eligible. And as an investor, naturally, we'd have an interest in — should eligibility apply to you folks, maybe issuing some form of public statement regarding that, since like I mentioned, there are numerous benefits.

Craig Tagawa

executive
#22

Right. That's something we'd do.

Leonard Dunn

analyst
#23

Yeah. This isn't really a question, but from what I understand, the SBA — if you walk into your bank — is going to give you 6 months of payroll as an interest-free loan, provided you commit to retaining every one of your employees for 6 months; and once those 6 months are up, the loan gets forgiven; so I honestly can't see any reason you'd pass that up.

Craig Tagawa

executive
#24

We're definitely going to check into that, Lenny. Thanks.

Shareholder

analyst
#25

Yes. I've been part of your company for a very long time, a shareholder for many years, and I'll soon be marking my 90th birthday. What I'm hoping for is this: is there any new product in development that you haven't talked about that could sort of send the share price soaring? Are there any new products you're working on to boost your volume for anyone across the range of instruments you currently offer?

Craig Tagawa

executive
#26

I think if you take a look at it, what we've made public is that we intend to upgrade some of our Gamma Knife sites with the Icon upgrade, which will let us handle some larger tumors.

Shareholder

analyst
#27

Right, I understand that. I have observed that; so what's the status there?

Craig Tagawa

executive
#28

So, we only — we finished one back in September at Kettering Medical Center; plus I believe we've shared that we're going to install another one at our Albuquerque location, Lovelace Medical Center. Thus those represent the initial 2 we'll have completed. Also, I believe we're aiming to collaborate with a few of the hospitals on the MRI-LINAC unit. So I think those are 2 items we're considering. And I'll hand it to Ernie Bates to weigh in should anything further come to his mind.

Ernest Bates

executive
#29

Yeah, Bob, one more thing I'd add — we're keeping an eye on some fairly recent technologies that have gotten the green light from the FDA and are already being sold. I believe this type of equipment has come up before during earlier calls, but Elekta, along with a business named ViewRay, each offer FDA-cleared linear accelerators featuring built-in MRI imaging; that's why people call them MRLs, or MR-Linacs. Before the pandemic arrived, interest had begun building among quite a few prospective clinical partners, here in the U.S. and abroad, in bringing this technology on board. So that area is absolutely something we continue monitoring very carefully. We're holding detailed conversations with both suppliers regarding possible revenue-sharing arrangements involving clinical partners.

Shareholder

analyst
#30

Do you think these companies will actually want those items once they take effect? You've clearly put a lot of work into improving things, and I just hope you continue.

Ernest Bates

executive
#31

That's right, Bob. Here in the U.S., we have around 4,000 linear accelerators spread among different institutions nationwide. Out of that 4,000, about 1,000 units get swapped out annually. As a result, we've come across hospitals wanting to trade in older linear accelerators for this new modality. Their problem is that this equipment costs much more than simply replacing a unit with a new LINAC. That's among the reasons we're seeing a fair amount of interest from hospital partners in reducing that capital risk through a partnership with American Shared. So in that space we see enormous opportunity, much like we did with the Gamma Knife 30-odd years ago when...

Shareholder

analyst
#32

Yeah. For you folks, the Gamma Knife is a wonderful development. And honestly, given that my remaining time is limited, I want to witness something substantial — roughly 35,000 shares are what I hold, and before I pass away, I'd love to watch that value climb. So continue expanding and keep performing well. You folks are straightforward and decent. I'm aware that tough rivals exist for you globally, even right here within this nation, so simply persist, and my confidence in you remains. So I appreciate your response to my question very much.

Craig Tagawa

executive
#33

I appreciate that, and may you stay in the best of health.

Ernest Bates

executive
#34

Thanks for that, Bob.

Analyst

analyst
#35

It looks like the interest expense dropped quite a bit. Could you talk about whether that comes from lower interest rates as you work on refinancing long-term debt? Or does it come from a smaller overall balance, or maybe some mix of the two? Anything you can share would help.

Craig Tagawa

executive
#36

I'll have Alexis take that one.

Alexis Wallace

executive
#37

Yeah, the main factor there is that we're reducing what we owe. As those balances shrink, less goes toward interest and more of each payment covers principal. Over the past 2 years, we've completed some refinancings. Often, when we do a reload and there's already a balance on the lease or debt, we'll refinance that sum at a somewhat reduced rate, so it's a mix of things.

Craig Tagawa

executive
#38

All right, Daryl — thanks. If he wants to, I'll hand things over to Dr. Bates so he can share his final remarks.

Ernest Bates

executive
#39

I want to express my appreciation to each of you for being with us today. While the battle against the COVID-19 pandemic goes on, the sites of American Shared Hospital Services are, at present, still operating so that we can keep serving people with cancer, who make up the bulk of what we do. With an eye past this pandemic, we think our position for expansion continues to be a strong one. We're eager to talk with all of you once more during the conference call for the first quarter of 2020, which happens in early May. In the meantime, everyone, remain strong and well. That's all.

Operator

operator
#40

Once more, many thanks. Everyone, that brings us to the end of today's call. We appreciate your joining us. You're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.